Contraindications of Pimitespib and instructions for those who are not suitable for use

1. Overview of Drugs

Pimitespib is a new oral HSP90 inhibitor, mainly used to treat patients with gastrointestinal stromal tumors (GIST), especially in advanced patients who have failed or are intolerant to previous treatments with imatinib, sunitinib and regorafenib. HSP90 is a molecular chaperone protein involved in the folding, stabilization and functional regulation of a variety of oncogenic proteins. Pimetibib inhibits the activity of HSP90 and degrades key oncogenic proteins in cancer cells, thereby inhibiting tumor growth.

Although pimetibib has shown certain efficacy in clinical practice, as a targeted therapy drug, its use still has certain contraindications and is not suitable for people, so doctors' advice needs to be strictly followed. Understanding contraindications and restrictions for special groups can help reduce serious adverse events and ensure medication safety.

2. Contraindications of pimetibib

According to the drug instructions and clinical practice, the main contraindications of pimoteb include the following categories:

1.Those who are allergic to pimetibib or excipients

Use is contraindicated in any patient who is allergic to pimetibib or other ingredients in the tablets. Allergies may manifest as severe allergic reactions such as rash, itching, difficulty breathing, laryngeal edema, or shock. Use must be strictly avoided to prevent life-threatening events.

2.Patients with severe hepatic insufficiency

Pimetibib is mainly metabolized by the liver. If the patient has severe liver damage (such as Child-Pugh C grade), the drug metabolism will slow down and the plasma concentration may increase significantly, increasing the risk of toxicity, including aggravation of liver damage, hematological toxicity and digestive system adverse reactions.

3.Patients with severe renal insufficiency or dialysis

Although pimetibib is primarily metabolized by the liver, patients with severely impaired renal function may have abnormalities in the clearance of the drug and its metabolites, leading to drug accumulation and increased risk of adverse events. Therefore, patients with severe renal insufficiency or undergoing dialysis should avoid using it or use it with caution under strict supervision by a doctor.

4.Pregnant and lactating women

Pimetibib has been shown to have toxic effects on the fetus in animal experiments and is therefore contraindicated in pregnant women. It is also not recommended for breastfeeding women because the drug may be excreted through breast milk and cause potential harm to the baby. Effective contraceptive measures must be taken during use, and medication must be avoided during lactation.

3. Not suitable for users

In addition to contraindications, although some patients have no absolute contraindications, they still belong to the group who are not suitable for use or need to be used with caution:

1.Patients with cardiac insufficiency

Pimetibib may cause QT prolongation of the QT interval or abnormal heart rhythm. Therefore, patients with heart failure, arrhythmia, previous myocardial infarction or severe heart disease should use it with caution under electrocardiogram monitoring. If necessary, adjust the dose or choose alternative treatment.

2.Patients with hematological abnormalities

If the patient has severe bone marrow suppression (such as neutrophils lower than 1.0×10⁹/L, platelets lower than 50×10⁹/L), the use of pimotebib may aggravate hematological toxicity and cause risks of infection, bleeding, etc. The blood picture should be corrected before considering medication.

3.Patients with serious digestive system diseases

Since the common side effects of pimetibib include nausea, vomiting, diarrhea and loss of appetite, use in patients with gastric ulcers, gastrointestinal bleeding or severe inflammatory bowel disease may aggravate symptoms and should be used with caution.

4.Patients combined with severe liver and kidney toxicity drugs

It is necessary to avoid simultaneous use with other drugs that may cause liver and kidney toxicity to avoid additive toxicity. Common medications to watch out for include certain antifungals, antivirals, and chemotherapy drugs.

4. Pre-medication assessment and monitoring recommendations

Before treatment with pimetibib, a comprehensive evaluation is recommended:

1.Basic examination: blood routine, liver and kidney function, electrocardiogram and blood pressure, etc. to evaluate the patient's overall condition.

2.Mutation detection: Confirm whether the patient's GIST or other tumor indications are eligible for HSP90 inhibitory treatment.

3.Regular follow-up: During treatment, hematological indicators, liver and kidney function and electrocardiogram need to be monitored every 2–4 weeks to detect adverse reactions early and deal with them promptly.

4. Dose adjustment: If mild to moderate liver function damage or hematological toxicity occurs, the drug can be temporarily discontinued or the dose reduced, and treatment can be resumed after the indicators recover.

Pimoteb is an innovativeHSP90 targeted drugs are suitable for the treatment of advanced GIST and other HSP90 dependent tumors. Its use must strictly follow the contraindications and restrictions for special groups, especially those allergic to drugs or excipients, severe liver and kidney insufficiency, and pregnant and lactating women. For patients with cardiac dysfunction, bone marrow suppression, or digestive system diseases, they should be used with caution or alternatives should be considered under the guidance of a professional physician. Through reasonable patient screening, pre-medication assessment and regular monitoring, the risk of adverse events can be effectively reduced, the safety and effectiveness of treatment can be ensured, and clinical benefits can be brought to patients.

Reference materials:https://www.drugs.com/